Role of prasugrel, a novel P2Y12 receptor antagonist, in the management of acute coronary syndromes

American Journal of Cardiovascular Drugs

Volumn 9, Issue 4, 2009, Pages 213-229

  Baker, William L ^a   White, C Michael ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 3A4; KETOCONAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PRASUGREL; PRAVASTATIN; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RANITIDINE; ROSUVASTATIN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIOVENOUS SHUNT; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROGENESIS; BLEEDING; BLEEDING TIME; BRAIN HEMORRHAGE; CELLULITIS; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FACE EDEMA; FOLLOW UP; GINGIVA BLEEDING; HEADACHE; HEART INFARCTION; HEMATOCHEZIA; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAINTENANCE THERAPY; NEUTROPENIA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOGENESIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATHEROSCLEROSIS; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; THIOPHENES; THROMBOSIS;

EID: 70349339368     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/1131209-000000000-00000     Document Type: Review

References (110)

1. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494
2. Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997; 78: 611-616
3. Ibanez B, Vilahur G, Badimon JJ. Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur Heart J 2006; 8 Suppl. G: G3-9
4. Packham MA, Mustart JF. Platelet aggregation and adenosine diphosphate/ adenosine triphosphate receptors: a historical perspective. Semin Thromb Hemost 2005; 31: 129-138
5. Boeynaems JM, Communi D, Gonzalez JS, et al. Overview of P2 receptors. Semin Thromb Hemost 2005; 31: 139-149
6. 12 receptor. Curr Pharm Des 2006; 12: 1255-1259
7. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A 1998; 95: 8070-8074
8. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405
9. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207
10. 12 receptor: a novel member of the P2Y family of receptors activated by extracellular nucleotides. Mol Pharmacol 2001; 60: 416-420
11. Cattaneo M, Akkawat B, Lecchi A, et al. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost 1991; 66: 694-699
12. Boneu B, Destelle G, on behalf of the Study Group. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996; 76: 939-943
13. Savi P, Nurden P, Nurden A, et al. Clopidogrel: a review of its mechanism of action. Platelets 1998; 9: 251-255
14. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000; 60: 347-377
15. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089
16. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996; 93: 215-222
17. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three anti-thrombotic drug regimens after coronary-artery stenting. N Engl J Med 1998; 339: 1665-1671
18. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full ANTicoagulation versus ASpirin and TIClopidine (FANTASTIC) study. Circulation 1998; 98: 1597-1660
19. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anti-coagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS) trial. Circulation 1998; 98: 2126-2132
20. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99: 2364-2366
21. Betrand ME, Rupprecht HJ, Urban P, et al., for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102: 624-629
22. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing per-cutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533
23. Steinhubl SR, Berger PB, Mann III JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420
24. Mueller C, Roskamm H, Neumann FJ, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol 2003; 41: 969-973
25. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) study. Circulation 2005; 111: 2099-2106
26. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolysis: the PCICLARITY study. JAMA 2005; 294: 1224-1232
27. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 5946-5950
28. Levine GN, Berger PB, Cohen DJ, et al. Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals. Expert opinion from the American Heart Association's Diagnostic and Interventional Catheterization Committee and Council on Clinical Cardiology, and the American College of Clinical Pharmacy's Cardiology Practice Research Network. Pharmacotherapy 2006; 26: 1537-1556
29. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature dis-continuation of dual antiplatelet therapy in patients with coronary artery stents: a scientific advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with Representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 378-402
30. Siller-Matula J, Schror K, Wojta J, et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393
31. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45: 1157-1164
32. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913
33. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251
34. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 2006; 114: e600-6
35. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 2005; 46: 1827-1832
36. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003; 9: 1123-1125
37. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803-2809
38. Pfisterer M, Brunner-LaRocca HP, Buser PT, et al., for the BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 2006; 48: 2584-2591
39. Eisenstein EL, Anstrom KJ, Kong DR, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 197: 159-168
40. Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacologic profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000; 129: 1439-1446
41. Sugidachi A, Asai F, Yoneda K, et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747. Br J Pharmacol 2001; 132: 47-54
42. 12 receptor inhibitor. Thromb Haemost 2005; 94: 593-598
43. 12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 37-83
44. Frelinger AL, Jakubowski JA, Barnard MR, et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007; 98: 192-200
45. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007; 5: 1545-1551
46. 12 receptors by prasugrel. Biochem Pharmacol 2007; 74: 1003-1009
47. 12 inhibitor: a single ascending dose study in healthy humans. Platelets 2006; 17: 209-217
48. 12 inhibitor: a multiple-dose study in healthy humans. Platelets 2006; 17: 218-226
49. Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006; 47: 377-384
50. 12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2006; 63: 421-430
51. Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007; 49: 167-173
52. 12 receptor antagonist activity. Semin Thromb Hemost 2005; 31: 184-194
53. Fayer Rehmal JL, Eckstein JA, Farid DA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Disp 2006; 34: 600-607
54. Farid DA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-741
55. Wickremsinhe ER, Tian Y, Ruterbories KJ, et al. Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method. Drug Metab Disp 2007; 35: 917-921
56. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Disp 2007;35:1096-1104
57. Hirota T, Asai H, Asai F, et al. Efficacy of CS-747, a new potent antiplatelet agent [abstract no. PII-5]. Clin Pharmacol Ther 1999; 65: 148
58. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrelatorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924
59. Dmall DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008; 24: 2251-2257
60. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazole on the anti-platelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 2508-2509
61. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260
62. Ho PM, Maddox TM, Wang L, et al. Proton pump inhibitors may attenuate the benefits of clopidogrel among ACS patients: empirical evidence from 3,311 ACS patients [abstract no. 6241]. Circulation 2008; 118 (18 Suppl.): S1165
63. Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study [abstract no. 3998]. Circulation 2008; 118 (18. Suppl.): S815
64. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract no. 3999]. Circulation 2008; 118 (18 Suppl.): S-815
65. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48: 475-484
66. O'Donoghue M, Wiviott SD, Murphy SA, et al. Absence of an interaction between drugs metabolized by cytochrome P450 enzymes and the benefit of treatment with prasugrel versus clopidogrel inpatients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 analysis [abstract no. 1032-143]. J Am Coll Cardiol 2009; 53 Suppl. A: A328
67. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37
68. Mitsios JV, Papathanasiou AI, Rodis FI, et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109: 1335-1338
69. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004; 164: 2051-2057
70. Waneweser P, Windecker S, Billinger M, et al. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. Am J Cardiol 2007; 99: 353-356
71. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007; 50: 291-295
72. Riondino S, Petrini N, Donato L, et al. Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. J Thromb Thrombolysis. Epub 2008 Jul 18
73. Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008; 28: 1483-1494
74. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173
75. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: e9-16
76. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007; 100: 331-336
77. 12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation 2005; 111: 3366-3373
78. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. Ann Intern Med 1991; 115: 256-265
79. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 2004; 44: E1-211
80. Wiviott SD, Trank D, Frelinger AL, et al., for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation - Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932
81. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the BEST Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48: 931-938
82. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOISE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 2005; 112: 2946-2950
83. Payne CD, Li YG, Brandt JT, et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 2008; 19: 275-281
84. Montalescot G, Sideris G, Cohen R, et al. Prasugrel 10 mg provides greater platelet inhibition than clopidogrel 900/150 mg in UA/NSTEMI ACS - the ACAPULCO study [abstract no. 4408]. Eur Heart J 2008; 29: 716
85. Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 2008; 156: s16-22
86. ClinicalTrials.gov. Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3) [ClinicalTrials.gov identifier NCT00642174]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Nov 18]
87. Wiviott SD, Antman EM, Gibson CM, et al., for the TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006; 152: 627-635
88. Wiviott SD, Braunwald E, McCabe CH, et al., for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-2015
89. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel - Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028-2033
90. Murphy SA, Antman EM, Wiviott SD, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29: 2473-2479
91. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomized trial. Lancet 2008; 371: 1353-1363
92. Wiviot SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intense oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel - Thrombolysis In Myocardial Infarction 38. Circulation 2008; 118: 1626-1636
93. Serebruany VL, Alberts MJ, Hanley DF. Prasugrel in the poststroke cohort of the TRITON trial: the clear and present danger. Cerebrovasc Dis 2008; 26: 93-94
94. Bhatt DL. Intensifying platelet inhibition: navigating between Scylla and Charybdis. N Engl J Med 2007; 357: 2078-2081
95. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337
96. Kaul S, Shah PK, Diamond GA. Weighted composite endpoint analysis of TRITON-TIMI 38: disconnect between analytical equivalence and clinical importance [abstract no. 4587]. Circulation 2008; 118 (18 Suppl.): S-916
97. Serebruany VL. Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. Am J Med 2009; 122: 407-408
98. ClinicalTrials.gov. A comparison of prasugrel and clopidogrel in acute coronary syndrome subjects (TRILOGY ACS) [ClinicalTrials.gov identifier NCT00699998]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Aug 26]
99. King SB, Smith SC, Hirshfeld JW, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 172-209
100. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based practice guidelines. 8th ed. Chest 2008; 133: 670-707S
101. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2006; 47: e1-121
102. Varenhorst C, Braun O, James S, et al. Greater inhibition of platelet 'aggregation with a prasugrel 60 mg loading dose compared with a clopidogrel 600 mg loading dose in aspirin-treated patients [abstract]. Eur Heart J 2007; Suppl.: 189
103. Winters KJ, Payne CD, Ernest CS, et al. Prasugrel 60 mg versus clopidogrel 600 mg: greater platelet inhibition with prasugrel is explained by higher concentrations of the active metabolite [abstract]. Eur Heart J 2007; Suppl.: 218
104. Bassand JP. Unmet needs in antiplatelet therapy. Eur Heart J 2008; 10 Suppl.: D3-11
105. Storey RF. Variability of response to antiplatelet therapy. Eur Heart J 2008; 10 Suppl.: A21-7
106. Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-1396
107. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175
108. ClinicalTrials.gov. Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS (CURRENT/OASIS7) trial [ClinicalTrials.gov identifier NCT00335452]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Aug 26]
109. Abuzahra M, Pillai M, Caldera A, et al. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents. Am J Cardiol 2008; 102: 401-403
110. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther 2007; 12: 205-212